Search research articles
Contact Us
Filters
Showing results (421-430 of 512) with videos related to
Page
of 52
Sort By:
The Journal of Clinical Investigation
|
December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Roman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 12, 2022
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey
Sara Pilotto, Alice Avancini, Jessica Menis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 1, 2025
Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry
Thomas Hueso, Justin Cagnat, Kaïssa Ouali, et al.
The New England Journal of Medicine
|
June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
BMC Medical Genomics
|
December 5, 2013
Integrated molecular portrait of non-small cell lung cancers
Vladimir Lazar, Chen Suo, Cedric Orear, et al.
The New England Journal of Medicine
|
June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Cells
|
June 24, 2022
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test
Damien Vasseur, Hela Sassi, Arnaud Bayle, et al.
Diagnostic and Interventional Imaging
|
June 8, 2025
Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer
Ghina Jardali, Littisha Lawrance, Lama Dawi, et al.
Nature Medicine
|
February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial
Benjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.
Page
of 52
Search research articles
Search
Showing results (421-430 of 512) with videos related to
Sort By:
Page
of 52
The Journal of Clinical Investigation
|
December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Roman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 12, 2022
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey
Sara Pilotto, Alice Avancini, Jessica Menis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 1, 2025
Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry
Thomas Hueso, Justin Cagnat, Kaïssa Ouali, et al.
The New England Journal of Medicine
|
June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
Ferdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
BMC Medical Genomics
|
December 5, 2013
Integrated molecular portrait of non-small cell lung cancers
Vladimir Lazar, Chen Suo, Cedric Orear, et al.
The New England Journal of Medicine
|
June 4, 2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, et al.
The Lancet. Oncology
|
November 11, 2018
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, et al.
Cells
|
June 24, 2022
Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test
Damien Vasseur, Hela Sassi, Arnaud Bayle, et al.
Diagnostic and Interventional Imaging
|
June 8, 2025
Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer
Ghina Jardali, Littisha Lawrance, Lama Dawi, et al.
Nature Medicine
|
February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial
Benjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.
Page
of 52